A groundbreaking 2024 review published in the Journal of Cannabis Research has compiled the latest scientific evidence. It examines how cannabinoids may interact with three of the most common cancer types: breast cancer, colorectal cancer, and prostate cancer. The comprehensive study was authored by researchers from multiple international institutions. It examines both laboratory and animal studies to illuminate the potential mechanisms through which cannabis compounds might affect cancer cell behavior.
Understanding the Science Behind Cannabis and Cancer
Cancer remains the second leading cause of death worldwide. Breast cancer is the most prevalent among women (30% of female cancer cases). Prostate cancer leads among men (17.7%). Colorectal cancer ranks as the second most common cancer in both sexes. Traditional treatments, while effective for many patients, often face challenges. These include drug resistance and significant side effects.
The human body contains an endocannabinoid system (ECS) consisting of cannabinoid receptors (CB1 and CB2). It includes naturally produced endocannabinoids and enzymes that break them down. Researchers have discovered that cancer cells often express these cannabinoid receptors. Sometimes they express them at elevated levels compared to healthy tissue. This opens the door to targeted therapeutic approaches.
Key Findings: Cannabis and Breast Cancer
The research reveals several noteworthy observations about cannabinoids and breast cancer:
Receptor Expression: Studies found that CB2 receptors are expressed in approximately 72% of breast tumors examined. Additionally, 91% of HER2-positive (more aggressive) breast cancers express CB2 receptors. This suggests a potential therapeutic target.
Laboratory Effects: Multiple cannabinoids demonstrated the ability to trigger apoptosis (programmed cell death) in breast cancer cells. They also inhibited their proliferation and migration. CBD showed particularly promising results as the most potent inhibitor among phytocannabinoids tested.
Animal Studies: When mice with mammary tumors were treated with THC and JWH-133 (a CB2 receptor agonist), researchers observed slower tumor growth. They noted smaller lesions and fewer tumors compared to control groups. The cannabinoid-treated mice also showed reduced lung metastasis.
Mechanism of Action: Cannabinoids appear to reduce levels of COX-2 and prostaglandin-E2. These compounds are associated with tumor growth and angiogenesis (blood vessel formation that feeds tumors).
Key Findings: Cannabis and Colorectal Cancer
Colorectal cancer research has yielded particularly interesting results regarding cannabidiol (CBD):
Overcoming Drug Resistance: One of the most significant findings involves CBD’s potential to help overcome resistance to oxaliplatin, a common chemotherapy drug. When CBD was combined with oxaliplatin, death rates in resistant cancer cells increased substantially compared to either treatment alone.
Anti-Metastatic Properties: CBD acts as an antagonist to GPR55, a receptor associated with cancer metastasis. By blocking this receptor, CBD reduced cancer cell adhesion, invasiveness, and migration in laboratory studies.
Preventive Potential: In animal studies, CBD pretreatment dramatically reduced the formation of aberrant crypt foci, polyps, and tumors. All of these are precancerous lesions. Results showed reduction compared to control groups.
Anti-Inflammatory Effects: Since chronic inflammation can contribute to cancer development, cannabinoids’ ability to reduce inflammatory cytokines like IL-6 and IL-8 in tumor-bearing mice represents another potential benefit.
Key Findings: Cannabis and Prostate Cancer
Prostate cancer cells have been found to highly express both CB1 and CB2 receptors. Higher expression correlates with more aggressive cancers:
Multiple Mechanisms: Cannabinoids demonstrated antiproliferative effects and induced apoptosis in prostate cancer cells. They caused cell cycle arrest and reduced migration and invasion in laboratory settings.
Targeting Cancer-Associated Fibroblasts: WIN-55 (a synthetic cannabinoid) significantly reduced the activity of cancer-associated fibroblasts. These are cells that support tumor growth and metastasis. It did so without harming normal fibroblasts.
Exosome Inhibition: CBD showed remarkable ability to reduce the release of exosomes and microvesicles from prostate cancer cells. These cellular messengers are associated with tumor spread and chemotherapy resistance. Treatment with 5 μM CBD reduced these vesicles by 98.1%.
Supporting Hormone Therapy: For patients receiving androgen-deprivation therapy (ADT), cannabinoids may help prevent the differentiation of cancer cells. This prevents their transformation into treatment-resistant neuroendocrine-like cells.
Palliative Benefits for Cancer Patients
Beyond potential anticancer effects, the review highlights cannabinoids’ established role in symptom management:
Pain Management: Studies show that cancer patients using THC required 33% less opioid medication while achieving equivalent or better pain relief. In one large observational study, over 50% of patients reported severe pain before cannabis treatment. Less than 5% reported such high scores after six months of use.
Night Sweats: Dronabinol (synthetic THC) provided relief from paraneoplastic night sweats in cancer patients. Some experienced complete resolution of symptoms.
Nausea and Quality of Life: Multiple studies document improvements in chemotherapy-induced nausea, appetite, and overall quality of life.
Important Considerations
While these findings are promising, the researchers emphasize several important caveats:
-
Most studies are preclinical: The majority of evidence comes from laboratory cell studies and animal models. Large-scale human clinical trials are still needed.
-
Dose matters: Some research suggests that low doses of cannabinoids might actually promote cancer cell proliferation. Higher therapeutic doses inhibit growth. This dose-dependent effect requires further investigation.
-
Not a replacement for standard care: These findings should not be interpreted as suggesting cannabis can replace proven cancer treatments.
-
Individual variation: Cancer types and subtypes respond differently to cannabinoids. Individual patient responses may vary.
Looking Forward
The convergence of evidence from multiple research groups worldwide suggests that cannabinoids warrant serious consideration. They show potential as adjunctive therapies in cancer treatment. As the researchers conclude, cannabinoids show “promising potential as adjunctive therapy” for breast, colorectal, and prostate cancers.
For patients interested in exploring cannabis as part of their wellness routine, consultation with healthcare providers remains essential. The evolving science continues to reveal the complex ways our endocannabinoid system interacts with health and disease.
This article summarizes peer-reviewed research published in the Journal of Cannabis Research (May 2024). It is provided for educational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals regarding cancer treatment decisions.
Source: ALSalamat HA, et al. “Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer.” J Cannabis Res. 2024;6(1):24. doi: 10.1186/s42238-024-00233-z
